TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a ...

Biocon Biologics receives Health Canada approval for Yesafili, the first Eylea biosimilar in Canada, with launch slated for ...

CHENNAI: Biocon Biologics, the biosimilars subsidiary of Biocon Ltd, said on Friday that Health Canada has granted a Notice ...

This approval paves the way for the launch of YESAFILI in Canada, scheduled for 04 July 2025. YESAFILI is the first ...

Biocon Biologics receives Health Canada approval for its biosimilar Yesafili injection, used to treat various eye ailments.

Bengaluru: Biocon Biologics Ltd ., a fully integrated global biosimilars company and a subsidiary of Biocon Ltd ., has ...

Indian drugmaker Biocon has announced that Health Canada has granted a Notice of Compliance for Yesafili (aflibercept), a ...

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch ...

YESAFILI is contraindicated in patients with Ocular or periocular infection, Active intraocular inflammation and Hypersensitivity to aflibercept. Endophthalmitis, retinal detachments, ...

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL) , a fully integrated ...

BRIDGEWATER, N.J. and BENGALURU, Karnataka, India, April 15, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code ...

YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions, is a biosimilar of its referen.